Trial Profile
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 22 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 22 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.